This site is password-protected.
Incorrect password. Please try again.
Bluetongue virus is quickly spreading across Europe and beyond, transmitted by biting midges (Culicoides).
Mortality rates up to 73% in sheep, causing enormous economic losses for farmers across the continent.
Current vaccines are minimally effective, and insecticides are expensive, harmful, and not targeted.
BiSafe harnesses naturally occurring skin bacteria to repel biting midges — providing herd-level protection against all midge-borne diseases.
Scientifically validated: selection of sheep skin bacteria significantly reduces Culicoides midge biting.
Brok et al (2024) — Selection of sheep skin bacteria to reduce biting by Culicoides midgesBy repelling midges, BiSafe prevents transmission of all midge-borne diseases — not just Bluetongue.
One application protects the entire herd, creating a collective defense shield for your livestock.
| BiSafe | Vaccines | Insecticides | |
|---|---|---|---|
| Efficacy | ✓ High | ~ Moderate | ✗ Low |
| Cost | $ | $$$ | $$ |
| Env. Impact | ✓ None | ~ Low | ✗ High |
| Easy Application | ✓ Yes | ✗ No | ~ Moderate |
Simple spray-on application — no veterinary expertise required.
100% natural, probiotic-based — zero chemicals, zero environmental harm.
Safe for animals, humans, and the environment — no harmful residues.
CHF 40/unit
CHF 100/unit
Save 17%
CHF 180/unit
Save 25%
Class Winner 2024 (UZH I) — Innosuisse Business Concept, awarded December 2024.
Validated core probiotic repellent through confirmed scientific research.
Field testing on livestock to validate efficacy under real-world conditions.
Regulatory authorization process for market entry.
Accepted in the UZH Innovation Grant Program.
Patent application.
PhD publication.
Commercial launch of BiSafe across DACH region and EU markets.
Leading BiSafe's scientific vision and product development with deep expertise in biology and microbiology.
hochstrasser@bisafebiologics.comBackground in Strategy Consulting, Finance & Operations in both large Tech companies and Startups.
seebacher@bisafebiologics.comExperience and background in Intellectual Property, Venture Capital and Corporate Law and Finance.
meier@bisafebiologics.comExperience in project management and leading a Swiss association. Expertise in IP law and business development.
scognamiglio@bisafebiologics.comHave a question or want to collaborate? Drop us a message.
Please sign in with your username and password.
Incorrect username or password. Please try again.
Unlock the investor area to load the protected investor materials.